| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| RFS/DFS | 0.23 [0.12, 0.45] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
safety endpoints 00 |
| AE leading to death (grade 5) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 39.67 [8.72, 180.45] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 55.77 [7.19, 432.80] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 4.55 [2.00, 10.32] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 8.75 [3.35, 22.86] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 34.09 [7.51, 154.62] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 90.55 [5.31, 1542.75] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 21.77 [4.78, 99.11] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 39.00 [10.59, 143.61] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 80.95 [10.39, 630.65] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 112.65 [6.61, 1919.31] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 5.83 [0.28, 119.27] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Dizziness TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Ear and labyrinth disorders TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 10.10 [0.54, 189.78] | | < 1 | | 0% | 1 study (1/-) | 6.3 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Gastritis TRAE (grade 3-4) | 3.81 [0.17, 86.56] | | < 1 | | 0% | 1 study (1/-) | 20.3 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 17.19 [0.96, 307.68] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 3.81 [0.17, 86.56] | | < 1 | | 0% | 1 study (1/-) | 20.3 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 12.37 [0.67, 227.41] | | < 1 | | 0% | 1 study (1/-) | 4.7 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 28.19 [1.62, 491.24] | | < 1 | | 0% | 1 study (1/-) | 1.2 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 5.83 [0.28, 119.27] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 17.19 [0.96, 307.68] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 31.26 [1.80, 542.70] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.72 [0.68, 10.90] | | < 1 | | 0% | 1 study (1/-) | 7.9 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 3.81 [0.17, 86.56] | | < 1 | | 0% | 1 study (1/-) | 20.3 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 5.83 [0.28, 119.27] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.87 [0.06, 56.97] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
